US FDA approves Boostrix vaccine for use during third trimester of pregnancy to prevent whooping cough in infants younger than two months of age

The US Food and Drug Administration (FDA) approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. The US FDA granted the approval to GlaxoSmithKline Biologicals.